Spencer Pharmaceutical (SPPH)

[awesome1_in_cc]

Everyone please be carefull..As most of you know I have been trading this for weeks and I am currently on the sideline. I hope you all do very well, I really do but the following just hit my FB page:

Otc Picks December 10 at 8:52am Reply• Report

Breaking News Alert!

"Spencer Pharmaceutical Formalizes Buyout Offer With Al-Dorra"

(See Full Breaking News Story Below)

------------------------------------------------------

Spencer Pharmaceutical Inc. (OTC: SPPH)

Detailed Quote: http://www.otcpicks.com/quotes/SPPH.php

To View Full Company Profile: http://www.otcpicks.com/

------------------------------------------------------

Breaking SPPH News:

December 10 - Spencer Pharmaceutical Formalizes Buyout Offer With Al-Dorra

Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announced today that is has formalized the buyout offer with the Al-Dorra Group as a successful results of meetings held in Montreal, Canada over the past week.

According to the terms of the formal buyout offer, Al-Dorra will acquire Spencer Pharmaceutical for $245 million USD on an all cash transaction to close on or before March 17, 2011. As per the terms of the formal offer, Al-Dorra reserves the right to acquire shares in the open market and Al-Dorra will deposit $500,000 in the company's account to be used to pay legal fees, and expenses associated with the ongoing business operations of Spencer Pharmaceutical.

"We are very satisfied with the terms of the buyout offer as it is very beneficial to our shareholders," said Dr. Max Arella, President of Spencer Pharmaceutical Inc. "I would personally like to thank His Excellency Hussein Al-Awaid for his time and travel commitment in formalizing the agreement with our board on behalf of our shareholders," further added Dr. Arella.

------------------------------------------------------

Company Overview

Spencer Pharmaceuticals Inc. (Pinksheets: SPPH) is a public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Their focus is on newly patented formulation of existing drugs from the incubation to the developmental stages or newly synthesized drugs able to cross the blood-brain barrier. The company's partners are experienced researchers providing years of research, now ready for the drug-development status.

Spencer is currently focusing on the development of 2 patented applications (ready for Human trial) in the treatment of Central Nervous System diseases and of Diabetes:

L’Institut National des Sciences Appliquées de Rouen (INSA Rouen) has discovered a new technology in the challenging area of drugs delivered to the Central Nervous System through an innovative approach that allows the crossing of the blood-brain barrier and dramatically reducing the side effects of drugs used for neurological diseases.

L’Universite du Québec à Montréal (UQAM) has discovered how to control the release of existing therapeutics molecules in order to increase their bio-availability and systemic efficacy.

The company's goal is to develop a portfolio of pro-drugs with the ability to outclass the current commercial drugs.

------------------------------------------------------

OTCPicks is not registered as a securities broker-dealer or an investment advisor either with the SEC or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site or in this email are suitable or adviseable for any person or that an investment in such securities will be profitable. For our disclosure and disclaimer details visit http://www.otcpicks.com/disclosure-details.htm

Disclosure: OTCPicks.com and affiliates have been compensated ten thousand dollars by a third party (IAB Media) for this current SPPH email promotion.